Adverum Biotechnologies/$ADVM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Adverum Biotechnologies
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Ticker
$ADVM
Sector
Primary listing
Employees
155
Headquarters
Website
ADVM Metrics
BasicAdvanced
$95M
-
-$8.81
-
-
Price and volume
Market cap
$95M
52-week high
$6.85
52-week low
$1.78
Average daily volume
753K
Financial strength
Current ratio
0.646
Quick ratio
0.582
Long term debt to equity
-149.365
Total debt to equity
-159.812
Profitability
EBITDA (TTM)
-191.441
Management effectiveness
Return on assets (TTM)
-79.02%
Return on equity (TTM)
-429.58%
Valuation
Price to book
-1.7
Price to tangible book (TTM)
-1.7
Price to free cash flow (TTM)
-0.668
Free cash flow yield (TTM)
-149.60%
Free cash flow per share (TTM)
-6.418
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
32.81%
3-year earnings per share growth (CAGR)
-17.71%
10-year earnings per share growth (CAGR)
-6.74%
What the Analysts think about ADVM
Analyst ratings (Buy, Hold, Sell) for Adverum Biotechnologies stock.
ADVM Financial Performance
Revenues and expenses
ADVM Earnings Performance
Company profitability
ADVM News
AllArticlesVideos
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
Business Wire3 weeks ago
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
Business Wire3 weeks ago
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
Reuters3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adverum Biotechnologies stock?
Adverum Biotechnologies (ADVM) has a market cap of $95M as of November 17, 2025.
What is the P/E ratio for Adverum Biotechnologies stock?
The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of November 17, 2025.
Does Adverum Biotechnologies stock pay dividends?
No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of November 17, 2025.
When is the next Adverum Biotechnologies dividend payment date?
Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.
What is the beta indicator for Adverum Biotechnologies?
Adverum Biotechnologies (ADVM) does not currently have a Beta indicator.